Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 85 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  MULGeY5kfGmxbjDBd5NigQ>? NH\pNngxNjVxMT:yMlUh|ryP NFrzZmw{KGh? MkX5doVlfWOnczD0bIUh[mG|YXygR2IhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2PwOlI3ODl5OEez
T24 BC  MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYqwMlUwOS9{LkWg{txO NYDZcGVEOjRiaB?= Mke4[Y5p[W6lZYOgd49z[W[nbnniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliZHXjdoVie2V? M2XYWlI3ODl5OEez
T24 BC  NYm4O4xrSXCxcITvd4l{KEG|c4PhfS=> MkT1Nk42KM7:TR?= M2rNNlI1KGh? MlXOd4Vve2m2aYrld{BDSyClZXzsd{B1dyC|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?= Mnn6NlYxQTd6N{O=
HepG2 NWHUPGhGTnWwY4Tpc44hSXO|YYm= NUfWWXVMOjEEoN88US=> MUGyOOKhcA>? MoTjdJJw\HWlZYOgZY4hcW62ZX7z[UBkgXSxcHzhd41q[yC4YXP1c4xqgmG2aX;uJINwenKnc4DvcoRqdmdidH:gZUBvd3SjYnzlJIRqdGG2YYTpc44hd2ZidHjlJGVTKGOrc4Tldo5{ M{jWWVI2QTN2MkOy
U-87 MG  NV7veno5TnWwY4Tpc44hSXO|YYm= MXuyNOKh|ryP NWPyXVJiOjUEoHi= MmnmbY5kemWjc3XzJIRwfWKuZT3t[Y1jemGwZTDic5Vv\CC|dIL1Z5R2emW| MVSyOVk{PDJ|Mh?=
HepG2 NXnUUXN2TnWwY4Tpc44hSXO|YYm= MnfrNlDDqM7:TR?= M1zrXlYwOjRiaB?= Mn3SbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS MoXjNlU6OzR{M{K=
U-87 MG  M4DMTWZ2dmO2aX;uJGF{e2G7 Mon5NlDDqM7:TR?= MV22M|I1KGh? MnXxbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS NEDOS3gzPTl|NEKzNi=>
HepG2 NE\k[5BHfW6ldHnvckBCe3OjeR?= NWnido5KOjEEoN88US=> NX[wOG9HPi9{NDDo NEjNSIhl\WO{ZXHz[ZMhVEN|LVnJJIRm\3KjZHH0bY9vyqCocn;tJFYhcA>? MlPuNlU6OzR{M{K=
U-87 MG  NHnIVndHfW6ldHnvckBCe3OjeR?= MVmyNOKh|ryP M1HveFYwOjRiaB?= MV7pcoNz\WG|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS|IITobZMh\my3eDDheEAzPGh? MlLFNlU6OzR{M{K=
HepG2 NWPJVXN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\IVo5sOjBxNECg{txO Mn;3NlQwPDhiaB?= NXK2WJg4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MmTWNlU6OzR{M{K=
U-87 MG  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiNlAwPDBizszN NUf3T45iOjRxNEigbC=> M{XKXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2nCelI2QTN2MkOy
A549 NEXkPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVewMlMuOTBizszN MWKyOE84OiCq M4ThTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHr6So8zPTZ7N{i5PS=>
H460 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMlMuOTBizszN M{PMS|I1Nzd{IHi= NI\JXndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFLBUFQzPTZ7N{i5PS=>
A549 MnjpRZBweHSxc3nzJGF{e3OjeR?= NYDFOoI6OS9|IN88US=> M2PEZ|Q5KGh? MV;pcoR2[2W|IHHwc5B1d3Orcx?= MWCyOVY6Pzh7OR?=
H460 NYDkSoZQSXCxcITvd4l{KEG|c4PhfS=> NFTJVlQyNzNizszN NEHEVGU1QCCq NHzJemdqdmS3Y3XzJIFxd3C2b4Ppdy=> NI\2c3YzPTZ7N{i5PS=>
A549 MVvGeY5kfGmxbjDBd5NigQ>? NWTMUVFOOyEQvF2= NIfpNGQ5KGh? M2PtZYJtd2OtczDBT3Qh[WO2aY\heIlwdg>? NGnhSHIzPTZ7N{i5PS=>
H460 MUHGeY5kfGmxbjDBd5NigQ>? NIC4clI{KM7:TR?= M2PlNFghcA>? MX\icI9kc3NiQVvUJIFkfGm4YYTpc44> NXns[ow1OjV4OUe4PVk>
A549 MkPlSpVv[3Srb36gRZN{[Xl? NGi2XHE{KM7:TR?= NVTtRYdjQCCq NGnOcmVjdG:la4OgcXRQWkNzLDDhcoQhTVKNLV3BVGsh[WO2aY\heIlwdiClb33ibY5m\CC5aYToJG1GUy1zNkK= MnLwNlU3QTd6OUm=
H460 NIrJbYFHfW6ldHnvckBCe3OjeR?= NWHmWpFzOyEQvF2= NWW1[YxHQCCq M{m3RoJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= NHjQPJQzPTZ7N{i5PS=>
RMG1 NWPFRXROS2WubDDWbYFjcWyrdImgRZN{[Xl? MX:xMVMxKM7:TR?= M{CwfVczKGh? NWDMZ5E5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVLKblQ3OjV3MUmxOFg>
RMG2 M1\EPGNmdGxiVnnhZoltcXS7IFHzd4F6 M2TJZVEuOzBizszN MXy3NkBp NXLWU3VO\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M1HYRlI2PTF7MUS4
KOC7C NVvob4ZOS2WubDDWbYFjcWyrdImgRZN{[Xl? NH62SpYyNTNyIN88US=> NFrwNlQ4OiCq M4Gzc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MYWyOVUyQTF2OB?=
HAC2 NXvKOWQ3S2WubDDWbYFjcWyrdImgRZN{[Xl? NHrOTGoyNTNyIN88US=> MYG3NkBp M2r3[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3PzNFI2PTF7MUS4
RMG2 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGnpSmQyNTNyIN88US=> Mn3iOFghcA>? MkK4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MYWyOVUyQTF2OB?=
OVISE M3;mdWNmdGxiVnnhZoltcXS7IFHzd4F6 NV7ib2VOOS1|MDFOwG0> MYm0PEBp Mnf6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NX3nWW5TOjV3MUmxOFg>
SKOV3 MlzxR4VtdCCYaXHibYxqfHliQYPzZZk> NEPn[o0yNTNyIN88US=> M1;QfFQ5KGh? MkT6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFXjb3kzPTVzOUG0PC=>
A2780 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWexMVMxKM7:TR?= Mn;3OFghcA>? NWTpRpFw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M{fsU|I2PTF7MUS4
RMG1 NGT3elRCeG:ydH;zbZMhSXO|c3H5 MX6zNEDPxE1? M4\2OVI1KGh? NHPFbIdqdmS3Y3XzJIFxd3C2b4Ppdy=> MY[yOVUyQTF2OB?=
RMG2 Mo\LRZBweHSxc3nzJGF{e3OjeR?= MoDKN|Ah|ryP NFnDbWMzPCCq MmDabY5lfWOnczDhdI9xfG:|aYO= M1XwTFI2PTF7MUS4
HCC1806 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXywMVExKM7:TR?= M2\DbVQ5KGh? NUfpe4ZXTUN3ME2yMlg16oDLwsJihKkxNjB5IN88US=> MXqyOVI6OzV5Nh?=
MDA-MB-231  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fP[lAuOTBizszN Mm\rOFghcA>? MlPJSWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?= NVzmdXBXOjV{OUO1O|Y>
GL-1 M3zFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDNZlYxNjIkgKOxNFDjiIoQvF2= M1O4flQ5KGh? M3v2fWlEPTB;OT65NUDPxE1? M13qWlI1QDhzNUC4
CLBL-1 NXz0eWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqwMlHjiJNzMEFihKnPxE1? NFyyOI01QCCq M2G2TWlEPTB;M{OuNEDPxE1? MYeyOFg5OTVyOB?=
UL-1 NInJe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\1dnZ1OC5z4pETNVAx6oDLzszN M2PjT|Q5KGh? M3zDSmlEPTB;Nz6wNUDPxE1? NVf4R|J[OjR6OEG1NFg>
Ema Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvtNE4y6oDVMUCw5qCK|ryP MUW0PEBp MmD6TWM2OD13OD63JO69VQ>? MX[yOFg5OTVyOB?=
PANC-1 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17qPFAuOjVizszN NViwd2hRPzJiaB?= NF\HdndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NV;1UG9xOjR3MUm3OVE>
MIA MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPy[WsxNTJ3IN88US=> MXW3NkBp MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MUmyOFUyQTd3MR?=
AsPC-1 NUPHWJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TNNlAuOjVizszN M{DtNFczKGh? NG\RbXFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXKyOFUyQTd3MR?=
PANC-1 NFv2SplHfW6ldHnvckBCe3OjeR?= MUiwMlUh|ryP MWSyOEBp MY\pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> MVGyOFUyQTd3MR?=
MIA Ml3VSpVv[3Srb36gRZN{[Xl? NY\vNlRROC53IN88US=> M3GxW|I1KGh? M1XrTolvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? NXnJVXR1OjR3MUm3OVE>
AsPC-1 NVuzWHN7TnWwY4Tpc44hSXO|YYm= M1TuRVAvPSEQvF2= M1GyelI1KGh? M4XyW4lvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? MYSyOFUyQTd3MR?=
U87MG NVjDdlhSS2WubDDWbYFjcWyrdImgRZN{[Xl? MlS5NE0zPSEQvF2= M2PCW|I1NTl4IHi= NY\OOpE6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NEThNWkzPDB4NUWyNi=>
SGC7901  M3:4cWZ2dmO2aX;uJGF{e2G7 NHjae4kxNjd3L{GwxsDPxE1? M3nle|Q5KGh? NViwV|RC\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh NYTUU3pGOjN7MUKyOFY>
MGC803  M1P2cmZ2dmO2aX;uJGF{e2G7 MYmwMlc2NzFywrFOwG0> M2PpUlQ5yqCq MWHk[YNz\WG|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy|wrC= M1WzdVI{QTF{MkS2
TykNu NYqwUFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwNTFOwG0> NYLrTHFuOjN6N{ewNVI>
TykNuR MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwNTFOwG0> MkHlNlM5PzdyMUK=
M41 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJ2Lkeg{txO NUjGPWpFOjN6N{ewNVI>
M41R NWnUeGJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2faVWlEPTB;MUmuPEDPxE1? NYXkPIhpOjN6N{ewNVI>
OVCAR8 NX7tbGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3C[JVKSzVyPUOxMlEh|ryP Mk\INlM5PzdyMUK=
HeyA8 NG\mTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[yTWM2OD1{ND6zJO69VQ>? MnuxNlM5PzdyMUK=
A2780CP Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKwZ4ZKSzVyPUeuOkDPxE1? MnH3NlM5PzdyMUK=
OVCAR5 NV\mVGJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHiTWM2OD14Lkeg{txO MYGyN|g4PzBzMh?=
A2780S NEPKTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF2LkWg{txO M3fQRlI{QDd5MEGy
MCAS MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLOZYZKSzVyPUGyMlUh|ryP M2TRXVI{QDd5MEGy
NCI-H727 M36xcmNmdGxiVnnhZoltcXS7IFHzd4F6 NFHPcpoxNTFyMDFOwG0> MmLyNlQwPzJiaB?= M4\sUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> M{HiNlIzPDl7NEO3
GOT1 NWDjfIlkS2WubDDWbYFjcWyrdImgRZN{[Xl? NWjjeFd6OC1zMECg{txO MorQNlQwPzJiaB?= NHjtOW9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MoPMNlI1QTl2M{e=
BON1 NYDESGVnS2WubDDWbYFjcWyrdImgRZN{[Xl? M3zlRVAuOTByIN88US=> MVuyOE84OiCq MUPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NW\NVJZCOjJ2OUm0N|c>
BON1 M1PqZmFxd3C2b4Ppd{BCe3O|YYm= NVj4VI9pOC1zMDFOwG0> MYeyOEBp NH\UeldqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MWOyNlQ6QTR|Nx?=
BON1 MofPSpVv[3Srb36gRZN{[Xl? NE\t[|g4NjVxMUCg{txO NVLRTWlJQCCq NEGyOpJl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhfGinIHHueIku[XCxcITveIlkKHC{b4TlbY5{KEKFTEKgZY5lKEKlbD3YUC=> MkHPNlI1QTl2M{e=
Kasumi-1 NYr5UWRzS2WubDDWbYFjcWyrdImgRZN{[Xl? MmnhNE0zOCEQvF2= MXGyOE81QCCq MnOz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M{DqNVIzPDB5MkK4
HL-60 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn3rNE0zOCEQvF2= NEHIfVIzPC92ODDo MoHS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MUGyNlQxPzJ{OB?=
Kasumi-1 NXHXUIZ7SXCxcITvd4l{KEG|c4PhfS=> M4P3SFExKM7:TR?= MnHmNlQhcA>? NX\JUGo1cW6mdXPld{BieG:ydH;zbZM> NV;NcFV3OjJ2MEeyNlg>
HL-60 Ml\XRZBweHSxc3nzJGF{e3OjeR?= M{LJU|ExKM7:TR?= MYKyOEBp MmHtbY5lfWOnczDhdI9xfG:|aYO= MYSyNlQxPzJ{OB?=
Kasumi-1 M4XRPGZ2dmO2aX;uJGF{e2G7 NEHSSYszNjVxNT:xNEDPxE1? Mn3jNlQhcA>? NVHD[3p3\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 M{DmXFIzPDB5MkK4
HL-60 MVrGeY5kfGmxbjDBd5NigQ>? MV:yMlUwPS9zMDFOwG0> MojSNlQhcA>? Mo\3[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6 NFr3coszOjRyN{KyPC=>
Kasumi-1 MoOySpVv[3Srb36gRZN{[Xl? M4\lOlIvPS93L{GwJO69VQ>? NFTNOWozPCCq NWT5UmlDcW6mdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFrOT|EwOiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlviNlI1ODd{Mki=
HL-60 MY\GeY5kfGmxbjDBd5NigQ>? NWjkWIFCOi53L{WvNVAh|ryP MUiyOEBp NHzsT3BqdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFLsWnQzOjRyN{KyPC=>
K562 MWnGeY5kfGmxbjDBd5NigQ>? NITyN4ozOCEQvF2= MXG0PEBp NVviboROcW6mdXPld{BifXSxcHjh[5nDqA>? NGPzN3kzOjRyN{KyPC=>
OCUT1 M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5NE4yNTNizszN MUi1JIQ> MnvybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NYDLT3VJOjJyOUCyO|E>
K1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jtOlAvOS1|IN88US=> NEP4ZmQ2KGR? NXGxZldbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlLkNlIxQTB{N{G=
OCUT1 NWjWT3l2TnWwY4Tpc44hSXO|YYm= MYmzJO69dQ>? NWHJTIVXOjRiaB?= MmfKZ4F2e2W|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>? NXXDS3Q5OjJyOUCyO|E>
CaOV3 NXy0c2FmS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn3HNU82NzFyIN88US=> MljrOFghcA>? MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJiY3;0doVifGWmIIfpeIgheGGlbHn0ZZhmdA>? MoHPNlE4PzVyNUS=
SKOV3 MVrDfZRwfG:6aXPpeJkhSXO|YYm= MX21JO69VQ>? M4LCSFQ5KGh? M4XYWYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MXSyNVc4PTB3NB?=
A2780 NILCXZlEgXSxdH;4bYNqfHliQYPzZZk> M2XJR|Uh|ryP MnzKOFghcA>? M1\XUYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> M{K1WlIyPzd3MEW0
HT-29  NWLUSFlSS3m2b4TvfIlkcXS7IFHzd4F6 M2D0ZlUh|ryP M2fIZVQ5KGh? M{\McIVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MYmyNVc4PTB3NB?=
A498 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XaVFAuPDBizszN NIP6UXI4OiCq NGD2NI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2rCOFIyPjR2MEWw
CAKI-1 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\uUVAuPDBizszN NXjPZXlSPzJiaB?= NI\ic5BKSzVyfkGwJO69VQ>? MX2yNVY1PDB3MB?=
769-P MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGwMVQxKM7:TR?= NVjqW4lOPzJiaB?= MV;JR|UxhjVvMUCg{txO MkHJNlE3PDRyNUC=
786-0 NWHnR5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXoNE01OCEQvF2= MVW3NkBp M163SGlEPTC-NTFOwG0> NFrqRWwzOTZ2NEC1NC=>
786-O MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjq[mIxNTJyIN88US=> MYO3NkBp MmXBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MXmyNVY1PDB3MB?=
CAKI-1 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqwMVIxKM7:TR?= MWm3NkBp NUP2PXZQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MX2yNVY1PDB3MB?=
769-P NIewVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMVIxKM7:TR?= NV7JUHFsPzJiaB?= MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Mk\MNlE3PDRyNUC=
A498 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzJSot3OC1{MDFOwG0> NVv6fHRMPzJiaB?= M3OzUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MnT1NlE3PDRyNUC=
CWR22RV1 NEDwcpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHnOcW8yOCEQvF2= M2Pkc|I1KGh? MlvabY5kemWjc3XzJJNmdnOrdHn2bZR6KG:oIHj1cYFvKEOZUkKyVnYyKGOnbHzzJJRwKHKjZHnheIlwdg>? M2\idlIyPDl4Mkez
CWR22RV1 NF;5O5ZCeG:ydH;zbZMhSXO|c3H5 NI\3U2YyOCEQvF2= MlTvNlQhcA>? NYTXPGJM\W6qYX7j[ZMhemGmaXH0bY9vKGmwZIXj[YQh[XCxcITvd4l{ NHH1SHczOTR7NkK3Ny=>
CWR22RV1 NUHnNJY6TnWwY4Tpc44hSXO|YYm= MVS1JO69VQ>? NGLkboczPCCq MWPy[YR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Qhe2mpbnnmbYNidnSueR?= MlLMNlE1QTZ{N{O=
HepG2  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LZPFUwOTBxMkCvOFAh|ryP M3nrWVI1NzR6L{eyJIg> MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1zuc|IxQDR{NEK1
Bel-7402 NEXteppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LyfVUwOTBxMkCvOFAh|ryP MmjJNlQwPDhxN{KgbC=> MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoDnNlA5PDJ2MkW=
HepG2  Moi1SpVv[3Srb36gRZN{[Xl? NIH0cHM2NzFyL{KwJO69VQ>? MX:yOEBp NYPu[3hFemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl NWe0NZE3OjB6NEK0NlU>
Bel-7402 M1faeGZ2dmO2aX;uJGF{e2G7 MWm1M|ExNzJyIN88US=> NGrZc4wzPCCq MXXy[ZN2dHS|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V? MXKyNFg1OjR{NR?=
HepG2  Ml\0RZBweHSxc3nzJGF{e3OjeR?= M3PJblUwOTBxMkCg{txO NGfnbHQzPC92ODDo NUnNbm1ycW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=> Moq0NlA5PDJ2MkW=
Bel-7402 NFfEfZBCeG:ydH;zbZMhSXO|c3H5 NWPOeXRQPS9zMD:yNEDPxE1? NEHM[mQzPC92ODDo MnXBbY5lfWOnczDhdI9xfG:|aYOgZZQhfGinIHzvcocufGmvZTDlfJBwe3W{ZR?= Mn62NlA5PDJ2MkW=
OAW-42 M4fPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSyR|U1OC12MDFOwG0> NFztVYg4OsLiaB?= MYjJR|UxhjFyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkXmNlA1ODV{OU[=
PA-1  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMVQxKM7:TR?= MX63NuKhcA>? M3zhXGlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWOyNFQxPTJ7Nh?=
SKOV3  MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n5S|AuPDBizszN MWW3NuKhcA>? Ml3XTWM2OH5|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWiyNFQxPTJ7Nh?=
A2780 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPxZnExNTJyIN88US=> M1TGV|Q5Nzd{IHi= M3;6dWlEPTEEoE5CpFPDqM7:bR?= M2DXWlIxPDB3Mkm2
A2780cis  NIDkOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqwMVIxKM7:TR?= M1ux[|Q5Nzd{IHi= NF\zbm1KSzVywrC9xsA3yqEQvH2= NHLDPGIzODRyNUK5Oi=>
SKW6.4 M{HuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfnXGkzNTFywrFOwG0> MUG0POKhcA>? M{Lac4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NUGxbW1GOjBzM{C5OlA>
MAVER NFnrdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTxOFdDOi1zMNMg{txO MYi0POKhcA>? NHP1RZRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXvzXXR4OjBzM{C5OlA>
BJAB NYrXOIJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPDdIEzNTFywrFOwG0> M1\DW|Q5yqCq NVvxe4k1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXnuS4dvOjBzM{C5OlA>
OCI MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnHSVVZOi1zMNMg{txO NITEPYc1QMLiaB?= MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXTTVo15OjBzM{C5OlA>
MOLM M1HRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyMVExyqEQvF2= NX7sS5ZSPDkEoHi= NY[1TpBUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MYOyNFE{ODl4MB?=
HL-60 NIqxTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfKNk0yOMLizszN MYK0POKhcA>? M{m5ZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4\rbFIxOTNyOU[w
SKW6.4 Mk\zRZBweHSxc3nzJGF{e3OjeR?= M{XNZlExyqEQvF2= M2fJNlI1NzR6IHi= M{jIVolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MnjsNlAyOzB7NkC=
MAVER MVHBdI9xfG:|aYOgRZN{e2G7 MmLBNVDDqM7:TR?= MkDDNlQwPDhiaB?= NFrlb3pqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 M{LEe|IxOTNyOU[w
BJAB MnH0RZBweHSxc3nzJGF{e3OjeR?= M1HHbFExyqEQvF2= NFHKS4UzPC92ODDo M4faN4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MlvZNlAyOzB7NkC=
OCI NWXTbXVpSXCxcITvd4l{KEG|c4PhfS=> NWfrenZbOTEEoN88US=> NWC2WW5{OjRxNEigbC=> Mo[xbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MXGyNFE{ODl4MB?=
MOLM NIPQNW9CeG:ydH;zbZMhSXO|c3H5 M4jxUFExyqEQvF2= MUeyOE81QCCq NF\yO|hqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NUju[mZoOjBzM{C5OlA>
HL-60 NH3rXVhCeG:ydH;zbZMhSXO|c3H5 NX:3N2gxOTEEoN88US=> MkfmNlQwPDhiaB?= Mm[wbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= Mk\ZNlAyOzB7NkC=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01224730 Completed Drug: perifosine Cancer AEterna Zentaris January 24 2012 Phase 1
NCT01049841 Completed Drug: perifosine + temsirolimus Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01048580 Completed Drug: Perifosine|Drug: Capecitabine Colon Cancer AEterna Zentaris|SCRI Development Innovations LLC October 2009 Phase 1
NCT00776867 Completed Drug: perifosine Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|AEterna Zentaris October 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID